A large number of studies have confirmed that FGFR3 mutation is a common genetic activity in bladder cancer and has become a promising molecular target for recurrence, prognosis, and treatment targets in bladder cancer [56, 57]. The gene discussed is FGFR3; the disease is urinary bladder cancer.